Related Experiment Video
Updated: Jun 21, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention
Robert E Feldmann1, Gottfried Kranz, Nicole Praschak-Rieder
1Department of Physiology and Pathophysiology, Division of Systems Physiology, University of Heidelberg Medical Center, Heidelberg, Germany. robert_feldmann@gmx.li
Abstract:
The authors report the case of a 32-year-old man who had been treated for anxiety and obsessive-compulsive disorder and had received 800 mg methylphenobarbital (MPB). After switching to a barbiturate-free schedule, his condition continued to be unstable for more than 21 MPB half-lives (approx. 30 days) and did not stabilize until MPB-metabolites dropped below their urinary detection limit. Considering that this article provides findings from a single patient, the authors use this experience to discuss and emphasize the importance of clinical control of barbiturates in psychiatry.
Related Concept Videos
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Barbiturates
Anxiolytic Drugs: Benzodiazepines and Buspirone
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.